A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA

Table 5

Change from baseline in VAS (in mm).

Visits	Curene® 500mg		Placebo
	N=25		N=25
	Mean (SD)	Change from baseline	Mean (SD)	Change from baseline
Baseline (Day 0)	52.37±6.41		52.79±4.47
Visit 2 (Day 7)	46.59±8.19	5.78±3.62	51.94±4.16	0.86±2.23
Visit 3 (Day 15)	41.71±9.35	10.66±6.08	49.28±4.40	3.51±4.99
Visit 4 (Day 30)	36.63±8.85	15.74±5.23	46.77±3.84	6.03±4.65
Visit 5 (Day 60)	27.26±11.95	25.11±8.66	44.83±4.27	7.97±5.29

Statistically significant (P <0.05) within group; statistically significant (P <0.05) between group.
Within group analysis by Pair t-test and between group analysis by repeated measures ANCOVA.